| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.2 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.055 | 0.2 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | PX-12 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | blebbistatin | CTRPv2 | pan-cancer | AAC | -0.11 | 0.2 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.053 | 0.2 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.2 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.2 |